Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × brexucabtagene autoleucel × 30 days × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡